帕金森病中的铁:分子机制和治疗潜力
Xv-Shen Ding1, Li Gao2, Zheng Han2
1Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi Province, 710038, China; Basic Medicine School, The Fourth Military Medical University, Xi'an, Shaanxi Province, 710038, China.
Ageing research reviews
|September 24, 2023
概括
铁,一种依赖于铁的细胞死亡,越来越多地与帕金森病 (PD) 的进展有关. 本综述探讨了铁亡机制如何导致PD的神经退行以及针对这种途径的潜在治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 涉及黑体中多巴胺能神经元的逐渐丧失,导致运动和非运动症状.
- 患病病因是复杂的,涉及蛋白质错折,线粒体功能障碍,氧化应激,炎症和铁的升高.
- 新出现的证据表明,铁,一种依赖铁的细胞死亡途径,在PD的进展中涉及铁.
研究的目的:
- 系统地审查铁灭的分子机制.
- 为了阐明铁和帕金森病病理学之间的联系.
- 检查PD模型中的ferroptosis及其治疗潜力.
主要方法:
- 在PD中分子途径的文献综述.
- 对神经退行症中铁亡的新兴证据的分析.
- 在PD动物模型和临床试验中对ferroptosis特征的审查.
主要成果:
- 在PD中的寡合性α-synuclein可能会通过活性氧物种和脂质过氧化触发铁.
- 在PD中失去多巴胺可能会增加神经元对铁亡的脆弱性.
- 铁亡代表了一种新的机制,有助于多巴氨基神经元退化.
结论:
- 铁亡是帕金森病发病的关键途径.
- 了解铁灭症为PD提供了新的见解.
- 向铁亡是一种有前途的治疗途径,用于帕金森病的管理.
相关概念视频
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


